NCT01409343 - TrasGEX™: Phase 1 Study in Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

December 31, 2013

Conditions

Solid Tumors

Interventions

DRUG

TrasGEX™

Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.

Trial Locations (5)

6020

Glycotope Investigational Site, Innsbruck

8036

Glycotope Investigational Site, Graz

20246

Glycotope Investigational Site, Hamburg

Unknown

Glycotope Investigational Site, Milan

Glycotope Investigational Site, Bellinzona